SAINT LAURENT, Quebec, Dec. 05, 2018 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) reported today, that the Company’s Board of Directors approved to amend the 2016 Stock Option Plan (the “Plan”) to increase the number of shares available for issuances under the Plan by 2,986,222 from 6,361,525 to 9,347,747, or 10% of the Company’s currently issued and outstanding shares. The amendment is subject to TSX-Venture Exchange acceptance.
The Amended 2016 Stock Option Plan will be available on EDGAR and SEDAR.
About IntelGenx:
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.
IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the Company can be found at www.intelgenx.com.
Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is2, defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com